Why the study?
Do GLP-1 receptor agonists increase the risk of heart failure or hospitalization for heart failure in patients with type 2 diabetes?
Do GLP-1 receptor agonists increase the risk of heart failure or hospitalization for heart failure in patients with type 2 diabetes?
This meta-analysis indicates that GLP-1 receptor agonists do not increase the risk of heart failure events in patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Affirms safe use of GLP-1 agonists in type 2 diabetes without heart failure concern; confirms neutral effect in meta-analysis of trials.
The current evidence suggests that GLP-1 agonists do not increase the risk of heart failure or hospitalization for heart failure among patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Li et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: